Tissue Factor Pathway Inhibitor (tfpi) Utilizing Patents (Class 514/14.5)
-
Patent number: 9018167Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: March 18, 2013Date of Patent: April 28, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 8912143Abstract: The present invention provides long half life genetically modified TFPI sequences (LTFPI) for anticoagulation. On the genetically modified TFPI sequence, the lysine at the carboxy-terminal sites 241, 254, 260 and 261 are replaced by alanin and the amino acid asparagine at glycosylation sites 117, 167, 228 and the amino acids serine and threonine at glycosylation sites 174 and 175 are substitutionally mutated. The present invention also provides methods of making the LTFPI through high efficient LTFPI expression from yeast production system.Type: GrantFiled: November 16, 2011Date of Patent: December 16, 2014Assignee: Fudan UniversityInventors: Duan Ma, Jingui Mu, Jiping Wang, Huijun Wang, Wang Liang
-
Publication number: 20140342987Abstract: The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject for amelioration of at least one sign or symptom of the disease. The invention also features kits.Type: ApplicationFiled: May 30, 2014Publication date: November 20, 2014Inventors: Ivo M. Francischetti, Robson de Queiroz Monteiro, Jose Marcos C. Ribeiro
-
Patent number: 8772238Abstract: The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject for amelioration of at least one sign or symptom of the disease. The invention also features kits.Type: GrantFiled: March 18, 2010Date of Patent: July 8, 2014Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Ivo M. B. Francischetti, Robson de Queiroz Monteiro, Jose Marcos C. Ribeiro
-
Patent number: 8652471Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.Type: GrantFiled: December 20, 2012Date of Patent: February 18, 2014Assignee: Novo Nordisk A/SInventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
-
Patent number: 8618263Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce clotting time in (a) human FVIII-deficient plasma and/or (b) human whole blood. Such antibodies have utility in the treatment of bleeding disorders and in the stimulation of blood clotting.Type: GrantFiled: December 18, 2009Date of Patent: December 31, 2013Assignee: Novo Nordisk A/SInventors: Ida Hilden, Jes Thorn Clausen
-
Patent number: 8563511Abstract: An improved non-human animal model of severe pulmonary arterial hypertension (PAH) and its use for testing of therapeutic agents that can treat symptoms of PAH are disclosed. In addition, the present application relates to the identification of several classes of therapeutic agents that, alone or in combination, can be used to treat or prevent PAH or at least reduce the severity of symptoms associated therewith. Both gene therapy and non-gene therapy approaches are described.Type: GrantFiled: October 6, 2005Date of Patent: October 22, 2013Assignee: University of RochesterInventors: R. James White, Mark B. Taubman
-
Publication number: 20130259863Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: ApplicationFiled: March 18, 2013Publication date: October 3, 2013Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 8507436Abstract: The present invention relates to isolated 18-mer peptides corresponding to amino acid residues 369-386 of human plasminogen activator inhibitor 1 (PAI-1) and fragments thereof, compositions that include such peptides, and uses of such compositions for treating thromboembolic diseases and pathological conditions associated with neurological damage.Type: GrantFiled: July 24, 2008Date of Patent: August 13, 2013Assignee: D-Pharm Ltd.Inventor: Abd Al-Roof Higazi
-
Patent number: 8481030Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: GrantFiled: December 12, 2011Date of Patent: July 9, 2013Assignee: Bayer Healthcare LLCInventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brueckner, Susanne Steinig, Peter Scholz
-
Patent number: 8450275Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: February 11, 2011Date of Patent: May 28, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 8361469Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.Type: GrantFiled: December 18, 2009Date of Patent: January 29, 2013Assignee: Novo Nordisk A/SInventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Sørensen
-
Publication number: 20120189673Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from a naturally occurring protein which modulates blood coagulation, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof, for use in the treatment or prevention of inflammation and/or excessive coagulation of the blood. Related aspects of the invention provide isolated polypeptides comprising or consisting of an amino acid sequence of SEQ ID NOs: 1 to 11, or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof which exhibit an anti-inflammatory and/or anti-coagulant activity, together with isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of inflammation and/or excessive coagulation.Type: ApplicationFiled: September 22, 2010Publication date: July 26, 2012Inventors: Martina Kalle, Nils Martin Malmsten, Praveen Papareddy, Victoria Rydengard, Artur Schmidtchen, Björn Ulrik Walse
-
Publication number: 20120028901Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: ApplicationFiled: February 11, 2011Publication date: February 2, 2012Applicants: BAXTER INTERNATIONAL INC., 3B PHARMACEUTICALS GMBH, BAXTER HEALTHCARE S.A.Inventors: MICHAEL DOCKAL, RUDOLF HARTMANN, MARKUS FRIES, FRIEDRICH SCHEIFLINGER, HARTMUT EHRLICH, ULRICH REINEKE, FRANK OSTERKAMP, THOMAS POLAKOWSKI
-
Patent number: 8062638Abstract: Provided herein is an animal having a persistent hypercoagulable state by implanting a cell, for example a tumor cell, in which the gene of human tissue factor is implanted to an experimental animal such as a mouse and then growing the cell, thereby persistently supplying human tissue factor to the experimental animal. This animal model is useful for research and development of therapeutic agents for diseases having a persistent hypercoagulable state. Also provided are preventive or therapeutic agents for diseases having a persistent hypercoagulable state, a hypercoagulable state resulting from infections, venous thrombosis, arterial thrombosis, and diseases resulting from the hypertrophy of vascular media, the agent comprising an antibody against human tissue factor (human TF) as an active ingredient.Type: GrantFiled: September 29, 2000Date of Patent: November 22, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Saito, Takehisa Kitazawa, Kazutaka Yoshihashi, Kunihiro Hattori
-
Patent number: 7993644Abstract: The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the invention.Type: GrantFiled: August 7, 2008Date of Patent: August 9, 2011Assignee: Purdue Pharma L.P.Inventor: Baiyang Wang
-
Patent number: 7951356Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.Type: GrantFiled: May 18, 2000Date of Patent: May 31, 2011Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao